The current influenza strain antigen for the 2019-2020 vaccine season produced by FSUE SPbSRIVS FMBA of Russia promptly for the WHO system (GISRS) was used by the key laboratory (NIBSC) for manufacturing the standard antigen and received catalog number 19/154. This indicates a high level of quality of SPbSRIVS products that meet not only the
Tagged under: , ,
April, 11, Latin American institute of biotechnology MECHNIKOV received honored guests from the Ministry of Health of Russia, Nicaraguan Institute of the Social Security (INSS), Federal medical-biological agency of Russia, CECMED and WHO/PAHO, who united in Managua to participate in Russian-Nicaraguan Technical Advisory Committee. This time meeting of the Technical Committee was highlighted by the
September 4-5, in Moscow took place the World Health Organization Conference on preventing the restoration of malaria transmission. In a discussion of current issues of malaria elimination in the European Region participated George Ignatiev, Deputy Director for Science Programs in SPbSRIVS. The malaria situation in Russian Federation in not the topic for discussion by public,
Tagged under: , ,
The influenza vaccine, developed by the St. Petersburg Research Institute of Vaccines and Serums of the Russian Federal Biomedical Agency, was issued a registration certificate in Nicaragua. This is the first step in the joint project by the Russian-Nicaraguan Intergovernmental Commission to support penetration by Russian immunobiological products of the Latin American markets. The registration
The pharmaceutical company Petrovax Pharm and the St. Petersburg Scientific Research Institute of Vaccines and Serums (SPbSRIVS) have signed an agreement on long-term strategic cooperation in the development, production, and introduction of innovative Russian vaccines into the public healthcare practice. In the near future, the companies plan to launch the joint full production cycle of
Tagged under: , ,
On February 18-20, a tripartite meeting was held by the representatives of Russia, Nicaragua, and the leadership of PAHO/WHO in Managua, Nicaragua. As a result of the meeting, a memorandum and an agreement of intent were signed. SPbSRIVS influenza vaccine and tuberculin, as well as its production facility in Krasnoye Selo will be registered in